0000000000361767

AUTHOR

Sebastiano Cavallaro

0000-0001-7590-1792

showing 6 related works from this author

Anticancer oral therapy: Emerging related issues

2010

The use of oral anticancer drugs has shown a steady increase. Most patients prefer anticancer oral therapy to intravenous treatment primarily for the convenience of a home-based therapy, although they require that the efficacy of oral therapy must be equivalent and toxicity not superior than those expected with the intravenous treatment. A better patient compliance, drug tolerability, convenience and possible better efficacy for oral therapy as compared to intravenous emerge as the major reasons to use oral anticancer agents among oncologists. Inter- and intra-individual pharmacokinetic variations in the bioavailability of oral anticancer drugs may be more relevant than for intravenous agen…

MaleCost-Benefit AnalysisPsychological interventionAdministration OralPharmacologyAntineoplastic AgentPharmacogenomicNeoplasmsMedicineDrug InteractionsInfusions IntravenouInfusions IntravenousCancermedia_commonOraltherapyGeneral MedicineTreatment OutcomeDrug InteractionOncologyTolerabilityPatient SatisfactionFemaleComplianceDrug-drug interactionHumanQuality of lifeDrugmedicine.medical_specialtyCostmedia_common.quotation_subjectPharmacokineticAntineoplastic AgentsDrug Administration ScheduleFollow-Up StudiePersistenceQuality of life (healthcare)Patient satisfactionPharmacokineticsHumansRadiology Nuclear Medicine and imagingCost-Benefit AnalysiAdverse effectIntensive care medicineDose-Response Relationship Drugbusiness.industryAdherencePharmacogenomicsNeoplasmPatient CompliancebusinessFollow-Up StudiesForecastingCancer Treatment Reviews
researchProduct

Genome-wide Analyses Identify KIF5A as a Novel ALS Gene

2018

© 2018 Elsevier Inc.

MaleAls geneGenome-wide association studyFAMILIAL ALSALS; axonal transport; cargo; GWAS; KIF5A; WES; WGS0302 clinical medicine80 and overPsychologyGWASKIF5AAetiologycargoAged 80 and over0303 health sciencesFrench ALS ConsortiumKinesinKINESIN HEAVY-CHAINCognitive Sciencesaxonal transportHumanHereditary spastic paraplegiaNeuroscience(all)Single-nucleotide polymorphismTARGETED DISRUPTIONArticle03 medical and health sciencesGeneticsHumansAmino Acid SequenceLoss functionAgedHEXANUCLEOTIDE REPEATNeuroscience (all)MUTATIONSAmyotrophic Lateral Sclerosis3112 Neurosciences1702 Cognitive Sciencemedicine.diseaseITALSGEN ConsortiumAnswer ALS Foundation030104 developmental biologyALS Sequencing ConsortiumHuman medicine1109 Neurosciences030217 neurology & neurosurgery0301 basic medicineALS; GWAS; KIF5A; WES; WGS; axonal transport; cargo[SDV]Life Sciences [q-bio]KinesinsNeurodegenerativeGenetic analysisGenomeAMYOTROPHIC-LATERAL-SCLEROSIS3124 Neurology and psychiatryCohort StudiesPathogenesisLoss of Function MutationMissense mutation2.1 Biological and endogenous factorsAmyotrophic lateral sclerosisNYGC ALS ConsortiumGeneticsGeneral NeuroscienceALS axonal transport cargo GWAS KIF5A WES WGSMiddle AgedPhenotypeSettore MED/26 - NEUROLOGIANeurologicalProject MinE ALS Sequencing ConsortiumKinesinWESFemaleAdultBiologyGENOTYPE IMPUTATIONALS; axonal transport; cargo; GWAS; KIF5A; WES; WGS; Adult; Aged; Aged 80 and over; Amino Acid Sequence; Amyotrophic Lateral Sclerosis; Cohort Studies; Female; Genome-Wide Association Study; Humans; Kinesin; Loss of Function Mutation; Male; Middle Aged; Young AdultNOYoung AdultRare DiseasesmedicineSLAGEN ConsortiumGene030304 developmental biologyClinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) ConsortiumNeurology & NeurosurgeryHuman GenomeNeurosciencesAXONAL-TRANSPORTBrain DisordersALS; axonal transport; cargo; GWAS; KIF5A; WES; WGS;Family memberDNA-DAMAGEMOTOR-NEURONS3111 BiomedicineCohort StudieALSGenomic Translation for ALS Care (GTAC) ConsortiumWGSAmyotrophic Lateral SclerosiGenome-Wide Association StudyALS; axonal transport; cargo; GWAS; KIF5A; WES; WGS; Neuroscience (all)
researchProduct

Genetic investigation of amyotrophic lateral sclerosis patients in south Italy: a two-decade analysis

2020

Amyotrophic lateral sclerosis (ALS) is a multifactorial disease characterized by the interplay of genetic and environmental factors. In the majority of cases, ALS is sporadic, whereas familial forms occur in less than 10% of patients. Herein, we present the results of molecular analyses performed in a large cohort of Italian ALS patients, focusing on novel and already described variations in ALS-linked genes. Our analysis revealed that more than 10% of tested patients carried a mutation in one of the major ALS genes, with C9orf72 hexanucleotide expansion being the most common mutation. In addition, our study confirmed a significant association between ALS patients carrying the ATNX-1 interm…

Male0301 basic medicineSanger sequencingAgingTime FactorsDiseaseCohort Studies03 medical and health sciencessymbols.namesake0302 clinical medicineRisk FactorsC9orf72HumansMedicineAmyotrophic lateral sclerosisRisk factorGenePathologicalAtaxin-1Genetic Association StudiesAmyotrophic lateral sclerosiSanger sequencingGeneticsDNA Repeat ExpansionC9orf72 ProteinMolecular analysibusiness.industryMolecular analysisGeneral NeuroscienceGenetic VariationAmyotrophic lateral sclerosismedicine.disease030104 developmental biologyItalyMutation (genetic algorithm)symbolsFemaleNeurology (clinical)Geriatrics and Gerontologybusiness030217 neurology & neurosurgeryDevelopmental BiologyNeurobiology of Aging
researchProduct

Genomic portrait of a sporadic amyotrophic lateral sclerosis case in a large spinocerebellar ataxia type 1 family

2020

Background: Repeat expansions in the spinocerebellar ataxia type 1 (SCA1) gene ATXN1 increases the risk for amyotrophic lateral sclerosis (ALS), supporting a relationship between these disorders. We recently reported the co-existence, in a large SCA1 family, of a clinically definite ALS individual bearing an intermediate ATXN1 expansion and SCA1 patients with a full expansion, some of which manifested signs of lower motor neuron involvement. Methods: In this study, we employed a systems biology approach that integrated multiple genomic analyses of the ALS patient and some SCA1 family members. Results: Our analysis identified common and distinctive candidate genes/variants and related biolog…

Candidate geneSpinocerebellar Ataxia Type 1Medicine (miscellaneous)lcsh:MedicineNetworkBiologyArticle03 medical and health sciences0302 clinical medicinemulti-omics; networkC9orf72medicineCustomized aCGHAmyotrophic lateral sclerosisGene030304 developmental biologyTAF15Genetics0303 health sciencesMulti-omicslcsh:Rmedicine.diseaseAmyotrophic lateral sclerosisPhenotypeSCA1-MNNGSSpinocerebellar ataxiaSpinocerebellar ataxia030217 neurology & neurosurgeryPathway
researchProduct

A novel S379A TARDBP mutation associated to late-onset sporadic ALS

2019

Since 2008, several groups have reported a lot of dominant mutations in TARDBP gene as a primary cause of Amyotrophic lateral sclerosis (ALS). Mutations in TARDBP gene are responsible for 4–5% of familial ALS (fALS) and nearly 1% of sporadic ALS (sALS). To date, over 50 dominant mutations were found in TDP-43 in both familial and sporadic ALS patients, most of which were missense mutations in the C-terminal glycine-rich region. Herein, we describe the clinical and genetic analysis of an Italian non-familial ALS patient with a late onset and a rapid disease progression, which led to the discovery of a novel TARDBP mutation. After neurological evaluation, molecular investigation highlighted t…

TDP-43DNA-Binding ProteinMutation MissenseLate onsetDermatologyBiologymedicine.disease_causeGenetic analysisTARDBP03 medical and health sciencesExon0302 clinical medicinemedicineHumansMissense mutation030212 general & internal medicineAmyotrophic lateral sclerosisAge of OnsetTARDBPGeneticsAged 80 and overMutationAmyotrophic Lateral SclerosisGeneral Medicinemedicine.diseaseDNA-Binding ProteinsPsychiatry and Mental healthMutationFemaleNeurology (clinical)Age of onsetALS030217 neurology & neurosurgeryAmyotrophic Lateral SclerosiHuman
researchProduct

Liver is not the unique site of synthesis of beta 2-glycoprotein I (apolipoprotein H): evidence for an intestinal localization.

1997

Apolipoprotein H is a protein of about 50 kilodaltons, structurally related to the regulators of the complement activation family. Its physiological function is poorly understood but it has been implicated in lipid metabolism and coagulative pathways. The major site of synthesis is thought to be the liver. Several reports indicate that apolipoprotein H is the antigen of the antiphospholipid antibodies and also behaves as an acute-phase reactant. Moreover, 40% of plasma apolipoprotein H is associated with very low-density lipoprotein, high-density lipoprotein, and postprandial chylomicrons. In this study we investigated other sites of synthesis by reverse transcription/polymerase chain react…

Apolipoprotein EApolipoprotein BClinical BiochemistryGene ExpressionBiologyPolymerase Chain ReactionCell LineHumansRNA MessengerIntestinal MucosaDNA PrimersGlycoproteinsMessenger RNABase SequenceLipid metabolismMolecular biologyImmunohistochemistryApolipoproteinsBiochemistryLiverbeta 2-Glycoprotein Ibiology.proteinlipids (amino acids peptides and proteins)Apolipoprotein C2Apolipoprotein HLipoproteinChylomicronInternational journal of clinicallaboratory research
researchProduct